CD274 and non-small cell lung carcinoma: conducted a meta‐analysis of all trials in advanced melanoma, NSCLC, and genitourinary cancers in which patients received nivolumab, pembrolizumab, or atezolizumab and in which tumoral PD‐L1 expression was assessed by immunohistochemistry.